Minerva Neurosciences Strengthens Advisory Board with Renowned Neurologist for Neurodegenerative Disease Therapies

NewcelX Appoints Renowned Neurologist to Scientific Advisory Board, Enhancing Its Commitment to Neurodegenerative Disease Therapies

NewcelX Ltd., a Zurich-based biotechnology firm, strengthens its Scientific Advisory Board with the appointment of Professor Tamir Ben-Hur, MD, PhD. Renowned for his expertise in neuroimmunology and stem-cell regenerative medicine, Professor Ben-Hur is affiliated with Hadassah University Medical Center and the Hebrew University of Jerusalem. His addition to the board signals a strategic move for NewcelX as it seeks to harness innovative therapies that integrate cell therapy with advancements in central nervous system (CNS) drugs, aimed at significantly improving patient outcomes on a global scale.

Professor Ben-Hur expresses enthusiasm about joining NewcelX, emphasizing the transformative potential of the company’s focus on developing therapies for neurodegenerative diseases. He acknowledges the pressing need for innovative solutions to conditions like amyotrophic lateral sclerosis (ALS) and Type 1 diabetes, which currently lack effective treatments. NewcelX’s Chief Scientific Officer, Professor Michel Revel, highlights that Ben-Hur’s extensive clinical experience and research background align perfectly with the company’s mission to target the underlying causes of these debilitating diseases through pioneering cell therapies. This appointment not only enhances the board's expertise but also reinforces NewcelX's commitment to advancing therapeutic options in the biotech landscape.

The foundation of NewcelX is bolstered by the merger of Kadimastem Ltd.'s advanced stem-cell platforms and NLS Pharmaceutic Ltd.'s expertise in CNS therapeutics. This integration allows the company to leverage a unique, scalable approach to regenerative treatments for various neurodegenerative and metabolic diseases. Operating from Ness Ziona, Israel, NewcelX aims to bridge the gap between stem-cell technologies and neuroscience, positioning itself as a frontrunner in developing groundbreaking therapies. The strategic appointment of Professor Ben-Hur is a clear indication of NewcelX’s forward-thinking strategy and its dedication to delivering innovative medical solutions.

In addition to the appointment, NewcelX continues to focus on expanding its research capabilities and enhancing its product pipeline. The integration of diverse expertise within its Scientific Advisory Board is expected to foster collaboration and accelerate the development of transformative therapies in the biotech sector.

As NewcelX moves forward, the company’s commitment to addressing unmet medical needs in neurodegenerative diseases remains central to its mission, promising a brighter future for patients worldwide.